Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 8/20 | 0.41 |
| ▸ | CDC7 | O00311 | 4/20 | 0.38 |
| ▸ | PIM1 | P11309 | 4/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.38 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | PDE9A | O76083 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22600592 | 0.93 | PARP14 (0.38) | PARP14CDC7PIM1CSNK2BCSNK2A1 | |
| SCHEMBL25795251 | 0.89 | CDC7 (0.38) | PARP14CDC7PIM1CSNK2BCSNK2A1 | |
| SCHEMBL22600708 | 0.88 | CDC7 (0.37) | CDC7PIM1CSNK2BCSNK2A1TMIGD3 | |
| SCHEMBL22600551 | 0.84 | PARP1 (0.44) | PARP14CDC7PIM1CSNK2BCSNK2A1 | |
| SCHEMBL22600702 | 0.82 | TMIGD3 (0.38) | CDC7PIM1CSNK2BCSNK2A1TMIGD3 | |
| SCHEMBL24378773 | 0.81 | PARP1 (0.44) | PARP14 | |
| SCHEMBL24378849 | 0.80 | PARP1 (0.41) | PARP14CDC7PIM1CSNK2BCSNK2A1 | |
| SCHEMBL30783587 | 0.80 | CDC7 (0.40) | PARP14CDC7PIM1CSNK2BCSNK2A1 | |
| SCHEMBL24378838 | 0.76 | GSK3A (0.31) | — | |
| SCHEMBL30784385 | 0.75 | TMIGD3 (0.41) | PARP14CDC7PIM1CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3967695-B1 | 1-(7-(QUINAZOLIN-4-YL)-2,7-DIAZASPIRO[3.5]NONAN-2-YL)PROP-2-EN-1-ONE DERIVATIVES AS KRAS INHIBITORS FOR THE TREATMENT OF CANCER | BETTA PHARMACEUTICALS CO LTD (CN) | 2024-01-17 | — | — | EP | disclosed |
| US-20230219956-A1 | QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | BETTA PHARMACEUTICALS CO.,LTD (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219956-A1 | QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | BETTA PHARMACEUTICALS CO.,LTD (CN) | 2023-07-13 | — | — | US | disclosed |
| WO-2022083616-A1 | QUINAZOLINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | 贝达药业股份有限公司 | 2022-04-28 | — | — | WO | disclosed |
| WO-2020216190-A1 | QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | 贝达药业股份有限公司 | 2020-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219956-A1 | QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCG2, NQO2 | PARP14 382/4885CDC7 765/4885PIM1 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.